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Abstract
Introduction: This is the first report to describe the feasibility and effectiveness of noninvasive positive pressure
ventilation in the secondary treatment of bronchopulmonary dysplasia.
Case presentation: A former male preterm of Caucasian ethnicity delivered at 29 weeks gestation developed
severe bronchopulmonary dysplasia. At the age of six months he was in permanent tachypnea and dyspnea and
in need of 100% oxygen with a flow of 2.0 L/minute via a nasal cannula. Intermittent nocturnal noninvasive
positive pressure ventilation was then administered for seven hours daily. The ventilator was set at a positive end-
expiratory pressure of 6 cmH2O, with pressure support of 4 cmH2O, trigger at 1.4 mL/second, and a maximum
inspiratory time of 0.7 seconds. Over the course of seven weeks, the patient’s maximum daytime fraction of
inspired oxygen via nasal cannula decreased from 1.0 to 0.75, his respiratory rate from 64 breaths/minute to 50
breaths/minute and carbon dioxide from 58 mmHg to 44 mmHg.
Conclusion: Noninvasive positive pressure ventilation may be a novel therapeutic option for established severe
bronchopulmonary dysplasia. In the case presented, noninvasive positive pressure ventilation achieved sustained
improvement in ventilation and thus prepared our patient for safe home oxygen therapy.
Introduction
Although there is some evidence that nasal noninvasive
ventilation has the potential to reduce the incidence of
bronchopulmonary dysplasia (BPD) in preterm new-
borns [1-5], there have been no studies of nasal nonin-
vasive positive pressure ventilation (NIPPV) in former
preterm infants with an established diagnosis of BPD
requiring high oxygen concentrations.
The main pathophysiological finding in BPD is a low
functional residual capacity accompanied by inefficient
gas mixing. Respiratory rate is increased [6]. Small air-
way function may worsen during the first year [7]. Sig-
nificant gas trapping is found in some BPD infants [8,9].
We report the response to intermittent nocturnal ther-
apy with nasal NIPPV in an infant with severe BPD.
Case presentation
Our patient was a male preterm of Caucasian ethnicity,
born at 29 weeks and one day gestation by Caesarean
section from a spontaneous dichorionic diamniotic twin
pregnancy complicated by preterm premature rupture of
the membranes with near-total loss of fluid nine days
before delivery. His birth weight was 940 g. A chest X-ray
showed pulmonary hypoplasia and grade 3 hyaline mem-
brane disease. Surfactant (beractant 100 mg/kg) was
given one hour after birth and repeated 24 hours later.
The patient was started on high frequency oscillatory
ventilation, with highest mean airway pressure 22
cmH2O on day one, and then switched to pressure-con-
trolled synchronized intermittent mandatory ventilation
on day 20 (highest peak inspiratory pressure 24
cmH2O). Inhaled nitric oxide was delivered for five days
in decreasing amounts (starting on day one with 26
ppm).
A left pneumothorax was drained on day four. The
clinical course was complicated by ventilator-associated
pneumonia on day 15. Tracheal aspirates grew
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coagulase-negative Staphylococci and Enterobacter cloa-
cae. Treatment consisted of piperacillin and tazobactam
with fusidic acid for two weeks. Extubation was success-
ful on day 26 after a two-day course of dexamethasone.
Ventilatory support was continued with nasal continu-
ous positive airway pressure (nCPAP; 8 cmH2O). BPD
was diagnosed at postmenstrual age 36 weeks. Shortly
thereafter, nasal swab cultures from copious upper air-
way secretions proved colonization with Stenotrophomo-
nas maltophilia, Escherichia coli as well as
Staphylococcus aureus which was treated with a two-
week course of oral sulfamethoxazole plus trimethoprim
and rifampin.
After 10 weeks nCPAP was switched to nasal cannula
flow of 2 L/minute with a fraction of inspired oxygen
(FiO2) of 0.5. Pulse oximetry target was set at arterial
oxygen saturation (SaO2) ≥ 90%. During subsequent
weeks the oxygen concentration had to be increased to a
FiO2 of 1.0 due to progressive deterioration of gas
exchange. At the age of six months our patient was in
constant dyspnea and tachypnea. Spontaneous inspira-
tory time was markedly shortened. Streaky densities and
cystic areas on a chest X-ray confirmed the diagnosis of
severe BPD. Echocardiography revealed concomitant pul-
monary hypertension with a tricuspid regurgitation pres-
sure gradient up to 30 mmHg. The FiO2 1.0 requirement
created a high risk of urgent reintubation in the event of
sudden desaturation. The boy’s increasing drive to move
around ruled out reintroducing nCPAP.
A ventilator set to NIPPV was installed providing noc-
turnal ventilatory support for an average of seven hours
every night. Ventilator settings are presented in Table 1.
For the first 18 days, sedation was provided with chloral
hydrate in decreasing amounts from 52 mg/kg to 7 mg/
kg per evening dose.
The features of the NIPPV device included a limited
dead space, highly sensitive automated circuit leak com-
pensation, and high trigger sensitivity. NIPPV was admi-
nistered via a nasal mask in a semirecumbent position
to enhance air entry into West zones 1 and 2 and to
diminish expansion of the radiologically over-distended
lung bases.
In the course of seven weeks of intermittent nocturnal
NIPPV, the spontaneous respiratory rate decreased from
64 breaths/minute to 50 breaths/minute, morning (post-
NIPPV) carbon dioxide dropped from 58 mmHg to 44
mmHg, and–most importantly–nasal cannula maximum
FiO2 decreased from 1.0 to 0.75 and the minimum FiO2
from 0.8 to 0.6 (Figure 1). At this point, NIPPV was
stopped and the baby was discharged on home oxygen
(flow rate 0.25 L/minute) at the postnatal age of eight
months. His weight increased by 200 g per week during
NIPPV therapy and reached 7490 g at discharge.
Two intercurrent lower respiratory tract infections
were managed on an outpatient basis. Our patient was
completely weaned off oxygen nine months after dis-
charge at the age of 17 months.
Neurological examination at the age of one year
showed less delay in the mental scale than in the psy-
chomotor scale (Bayley II) with scores of 76 and 56,
respectively. Free walking was achieved at 22 months of
age.
Conclusion
The clinical course of this ex-preterm boy suggests that
secondary NIPPV therapy has the potential to improve
severe BPD. A course of nocturnal intermittent NIPPV
in a timely manner (seven weeks) improved ventilation
and reduced oxygen need to a degree which provided
sufficient safety for subsequent home oxygen therapy.
Its positive effect was essential for our patient’s dis-
charge after eight months of hospital stay. In terms of
practicability, NIPPV was superior to nCPAP in that it
reliably avoided hypoventilation when the child initially
needed sedation to tolerate a nasal mask.
According to the literature, a bundle of different
mechanisms may have contributed to the improvement
observed. Synchronized NIPPV is known to increase
functional residual capacity [4], enhance ventilation uni-
formity [5], improve respiratory drive [10,11], lead to
greater lung recruitment [12] and decrease inspiratory
effort and respiratory work in comparison to continuous
flow nCPAP [13,14]. The duration of ventilatory support
is shorter with primary use of NIPPV than with nCPAP
[15].
We think this observation provides useful information
on NIPPV in established BPD before larger randomized
studies are performed on this topic. Further studies
incorporating lung function tests should identify the
level of respiratory support at which the repetitive sti-
mulus of nocturnal NIPPV exerts most of its positive
influence. It would be interesting to find out how
NIPPV propagates lung remodelling or if it even has the
potential to accelerate lung maturation in severe BPD.
Consent
Written informed consent was obtained from the
patient’s parents for publication of this case report. A
Table 1 Ventilator settings for NIPPV
Pressure support 4 cmH2O
Positive end-expiratory pressure 6 cmH2O
Trigger 1.4 mL/second
Ramp 25 ms
Expiratory trigger sensitivity 10%
Backup respiratory rate 8/minute
Maximum inspiratory time 0.7 seconds
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copy of the written consent is available for review by the
Editor-in-Chief of this journal.
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Figure 1 Decrease in FiO2 requirement over seven weeks of nocturnal NIPPV. Open rectangles and blue lines: oxygen concentrations
(maximum and minimum for each day) delivered via nasal cannula during daytime; full rectangles and green lines: oxygen concentrations for
nocturnal NIPPV. Oxygen saturation target was set at ≥ 90%.
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